# FDA Approves First Oral PCSK9 Inhibitor for LDL Cholesterol Lowering in Adults

> fda · REPORTED · 2026-07-16

On July 16, 2026 the FDA approved the first oral therapy that inhibits PCSK9 to lower LDL cholesterol in adults with high cholesterol, representing a major step beyond injectable PCSK9 inhibitors and potentially transforming the lipid-lowering treatment landscape for cardiovascular risk reduction.

About FDA / Oral PCSK9 Inhibitor (first approved): The first oral PCSK9 inhibitor is a small-molecule cardiovascular drug targeting the PCSK9 protein to reduce LDL cholesterol, offering a pill-based alternative to existing injectable PCSK9-inhibiting biologics for patients at elevated cardiovascular risk.

- Company: FDA / Oral PCSK9 Inhibitor (first approved)
- Sector: cardiology
- Primary source: https://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.